| 2.13 0.04 (1.91%) | 10-15 14:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.62 |
1-year : | 3.06 |
| Resists | First : | 2.25 |
Second : | 2.62 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.84 |
Second : | 1.6 |
| MAs | MA(5) : | 2.04 |
MA(20) : | 1.85 |
| MA(100) : | 1.74 |
MA(250) : | 1.83 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.6 |
D(3) : | 80.9 |
| RSI | RSI(14): 69.9 |
|||
| 52-week | High : | 2.71 | Low : | 1.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMMP ] has closed below upper band by 12.5%. Bollinger Bands are 128.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.12 |
| Low: | 1.94 - 1.95 | 1.95 - 1.97 |
| Close: | 2.07 - 2.09 | 2.09 - 2.11 |
Tue, 14 Oct 2025
Immutep Completes FDA Project Optimus, Advances Efti Trials - TipRanks
Mon, 13 Oct 2025
Immutep (IMMP) Receives FDA Approval for Optimal Dose in Cancer Treatment - GuruFocus
Mon, 13 Oct 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements - Stock Titan
Sun, 12 Oct 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements - Sahm
Mon, 08 Sep 2025
First-Ever Neoadjuvant Efti Combo Trial in Soft Tissue Sarcoma: Immutep to Present Phase II Results - Stock Titan
Thu, 28 Aug 2025
Immutep Limited (IMMP) Stock Analysis: Exploring a 472% Potential Upside in Immunotherapy Innovations - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 1.22e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4,290 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.288e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 35.4 % |
| Return on Equity (ttm) | -22.7 % |
| Qtrly Rev. Growth | 5.04e+006 % |
| Gross Profit (p.s.) | 6.29 |
| Sales Per Share | -24.43 |
| EBITDA (p.s.) | -3.73311e+007 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 32.16 |
| Dividend | 0 |
| Forward Dividend | 4.26e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|